Under the collaboration deal, NCI and NHGRI will apply Horizon’s rAAV gene editing technology (GENESIS) to engineer human isogenic disease models for its researchers.
In addition, X-MAN (gene X- Mutant and Normal) cell lines will be developed annually to bolster basic research and translational medicine.
The initial set of 18 projects from eight laboratories will develop disease models for melanoma, prostate, colon and kidney cancer, genes involved with chromatin and chromosome function, and cell lines complementary to existing mouse cancer disease models.